Skip to main content
Industry News
Company receives $1.5M grant for FVIII, emicizumab test

The DNA Medicine Institute received a $1.5 million grant from the NIH to aid in the development of its fingerstick point-of-care technology that monitors Helimbra, or emicizumab, and factor VIII blood levels in people with hemophilia A. The device could be especially useful in developing countries.

Full Story: